Independent health-science reporting · Evidence ratedEvidence rated
Independent health-science reporting
Beyond today’s standard of care.
Every story carries an evidence rating, named sources, and a plain account of what remains uncertain.
The Envita founder’s precision-medicine vision brings tumor profiling and targeted delivery into the same conversation. His team’s CIPI work offers a concrete example—and questions that further research must answer.
A survey-based study shows higher odds of post-diagnosis cannabis use among cancer survivors reporting average or below average mental health.
A cross-sectional registry analysis shows a marked rise in trials initiated after 2016 and a significant increase in industry sponsorship.
An economic simulation shows that blood-based gastric cancer screening is too expensive for average-risk individuals.
Cancer Innovation
Treatment, resistance, and the science reshaping oncology.
10 stories
Precision Medicine
Matching treatment to biology, one patient at a time.
10 stories
Diagnostics
Detection, monitoring, and the limits of early testing.
2 stories
Integrative & Supportive Care
Tolerability, recovery, and quality of life during treatment.
7 stories
Research & Trials
What is being studied, where, and what it would prove.
8 stories
Announcements, paid press releases, and sponsored features. This material is not produced by the NSH editorial desk.
The agency approved the estrogen receptor antagonist for use in combination with a CDK4/6 inhibitor.
October 14, 2026
The agency approved the kinase inhibitor for adult patients with locally advanced or metastatic disease.
September 15, 2026
